From XenoMouse® Technology to Panitumumab (ABX-EGF)
Recent success of antibody therapeutics in oncology has revived a keen interest in the development of monoclonal antibodies (mAbs) for the treatment of cancer. To date, eight mAbs have been approved in the United States for the treatment of hematological malignancies or solid tumors. The increased success has been largely attributed to advances in antibody technology such as chimerization and humanization of mAbs and the development of fully human antibodies allowing for reduction in immunogenicity and creation of antibodies of desired affinity and isotype. XenoMouse® technology is a technology that allows for the generation of fully human mAbs in transgenic mice. Using this technology, the anti-epidermal growth factor receptor (EGFR) antibody, panitumumab, has been created.
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR mAb. Panitumumab binds EGFR with high affinity, inhibits ligand-dependent receptor activation, and effectively inhibits the growth of multiple human tumor xenografts in mouse models. To date, in phase 1 and phase 2 clinical studies, panitumumab has been generally well tolerated, exhibited no immunogenicity, and demonstrated low interpatient and intrapatient pharmacokinetic variability. Objective responses have been observed in patients with metastatic colorectal cancer and advanced renal cell carcinoma.
Key WordsPanitumumab ABX-EGF EGFR mAb cancer XenoMouse targeted therapy IgG2
Unable to display preview. Download preview PDF.
- 2.Dillman RO. Human antimouse and antiglobulin responses to monoclonal antibodies. Antibody Immunocon Radiopharm 1990; 3:1–15.Google Scholar
- 4.Morrison S, Oi VT. Chimeric immunoglobulin genes. In: Hongo T, Alt FW, Rabbitts TH (eds.). Immunoglobulin genes. London: Academic, 1989:260–274.Google Scholar
- 10.Miller KD, Rugo HS, Cobleigh MA, Marcom PK, Chap LI, et al. Phase III trial of capecitabine (Xeloda®) plus bevacizumab (Avastin®) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. In: 26th Annual San Antonio Breast Cancer Symposium 2002; 12: 11.Google Scholar
- 21.Modjtahedi H, Dean C. The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer. Intl J Oncol 1994; 4:277–296.Google Scholar
- 30.AstraZeneca UK Ltd. Iressa™ (gefitinib tablets) product package insert. AstraZeneca, Wilmington, DE, 2003.Google Scholar
- 31.Imclone Systems and Bristol-Myers Squibb. Erbitux™ (Cetuximab) product package insert. Imclone Systems Inc., Branchburg, NJ, and Bristol-Myers Squibb Company, Princeton, NJ, 2004.Google Scholar
- 40.Yang XD, Wang P, Fredlin P, Jia XC, Oppenheim JJ, Davis CG. Preclinical evaluation of ABX-EGF as a potent anti-tumor agent. Proc Annu Meet Am Assoc Cancer Res 2002; 43:1004 (abstract).Google Scholar
- 41.Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Therapeutic potential of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer treatment. Proc Am Soc Clin Oncol 2000; 19:41a.Google Scholar
- 42.Yang XD, Wang P, Fredlin P, Davis CG. ABX-EGF, a fully human anti-EGF receptor monoclonal antibody: inhibition of prostate cancer in vitro and in vivo. Proc Annu Meet Am Assoc Cancer Res 2002; 21:116b (abstract).Google Scholar
- 43.Wang P, Fredlin P, Davis CG. Yang XD. Human anti-EGF receptor monoclonal antibody ABX-EGF: a potential therapeutic for the treatment of prostate cancer. Proc Annu Meet Am Assoc Cancer Res 2002; 43:913 (abstract).Google Scholar
- 44.McDorman K, Freemen DJ, Bush T, Cerretti D, Fanslow W, Starnes C, et al. ABX-EGF tumor penetration and EGFR saturation correlate with pharmacokinetic, pharmacodynamic, and antitumor activity in an A431 xenograft model system. Proc Annu Meet Am Assoc Cancer Res. 2004; 45(Suppl):109 (abstract).Google Scholar
- 48.Figlin RA, Belldegrun AS, Crawford J, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results. Proc Am Soc Clin Oncol 2002; 21:10a.Google Scholar
- 49.Rowinsky E, Schwartz G, Dutcher J, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFr) monoclonal antibody: phase 2 clinical trial in renal cell cancer (RCC). In: 14th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Frankfurt, 2002:1.Google Scholar
- 50.Rowinsky F, Schwartz G, Gollob J, Thompson J, Vogelzang N, Figlin R, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22:3003–3015.PubMedCrossRefGoogle Scholar
- 51.Roskos L, Lohner M, Osbern K, Pasumarti R, Lu H, Funelas C, et al. Optimal dosing of ABX-EGF in cancer patients. Int J Cancer 2002; 13(Suppl):444.Google Scholar
- 52.Meropol NJ, Berlin J, Hecht JR, et al. Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003; 22:256.Google Scholar